CA3035147A1 - Depot systems comprising glatiramer acetate - Google Patents
Depot systems comprising glatiramer acetate Download PDFInfo
- Publication number
- CA3035147A1 CA3035147A1 CA3035147A CA3035147A CA3035147A1 CA 3035147 A1 CA3035147 A1 CA 3035147A1 CA 3035147 A CA3035147 A CA 3035147A CA 3035147 A CA3035147 A CA 3035147A CA 3035147 A1 CA3035147 A1 CA 3035147A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- depot formulation
- glatiramer
- depot
- symptom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Resins (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Chemical Vapour Deposition (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381598P | 2016-08-31 | 2016-08-31 | |
| US62/381,598 | 2016-08-31 | ||
| PCT/IL2017/050882 WO2018042415A1 (en) | 2016-08-31 | 2017-08-09 | Depot systems comprising glatiramer acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3035147A1 true CA3035147A1 (en) | 2018-03-08 |
Family
ID=61300274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3035147A Pending CA3035147A1 (en) | 2016-08-31 | 2017-08-09 | Depot systems comprising glatiramer acetate |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12370233B2 (enExample) |
| EP (2) | EP4252849B1 (enExample) |
| JP (1) | JP7193448B2 (enExample) |
| CN (1) | CN109982712A (enExample) |
| AU (1) | AU2017319728B2 (enExample) |
| BR (1) | BR112019003594A2 (enExample) |
| CA (1) | CA3035147A1 (enExample) |
| DK (1) | DK3506921T3 (enExample) |
| ES (2) | ES2952044T3 (enExample) |
| FI (1) | FI3506921T3 (enExample) |
| HR (2) | HRP20230738T1 (enExample) |
| HU (2) | HUE062393T2 (enExample) |
| IL (2) | IL301455B2 (enExample) |
| LT (1) | LT3506921T (enExample) |
| MX (1) | MX2019002284A (enExample) |
| PL (2) | PL4252849T3 (enExample) |
| PT (1) | PT3506921T (enExample) |
| RS (2) | RS66690B1 (enExample) |
| SI (1) | SI3506921T1 (enExample) |
| SM (2) | SMT202500136T1 (enExample) |
| WO (1) | WO2018042415A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| WO2018042423A1 (en) | 2016-08-28 | 2018-03-08 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| IL316573A (en) | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| US12514908B2 (en) | 2021-07-05 | 2026-01-06 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| WO2023170493A1 (en) * | 2022-03-07 | 2023-09-14 | Hadidi Naghmeh | Drug delivery using a parenteral pharmaceutical composition |
| CA3244202A1 (en) | 2022-03-17 | 2023-09-21 | Mapi Pharma Ltd. | DEPOSIT SYSTEMS INCLUDING CARIPRAZINE OR SALTS THEREOF |
Family Cites Families (187)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| DE3673317D1 (de) | 1985-10-11 | 1990-09-13 | Duphar Int Res | Automatische spritze. |
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| HU221294B1 (en) | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5578442A (en) | 1992-03-23 | 1996-11-26 | Vivorx, Inc. | Graft copolymers of polycationic species and water-soluble polymers, and use therefor |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5643605A (en) | 1993-10-25 | 1997-07-01 | Genentech, Inc. | Methods and compositions for microencapsulation of adjuvants |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5858964A (en) | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
| IT1276690B1 (it) | 1995-06-09 | 1997-11-03 | Ira Srl | Sistema di inclusione a rilascio controllato di acido glicolico in beta-ciclodestrine e procedimento di preparazione di detto sistema |
| EP0817619A4 (en) | 1996-01-24 | 1999-02-03 | Us Army | NEW POLY (LACTID / GLYCOLID) MICROSPHERES WITH DELAYED RELEASE WITHOUT INITIAL SHOCK |
| ATE239041T1 (de) | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| US5792477A (en) | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
| US20070185032A1 (en) | 1996-12-11 | 2007-08-09 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| US5945126A (en) | 1997-02-13 | 1999-08-31 | Oakwood Laboratories L.L.C. | Continuous microsphere process |
| AR012448A1 (es) | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
| US6454746B1 (en) | 1997-06-04 | 2002-09-24 | Eli Lilly And Company | Medication delivery apparatus |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| JP2002503658A (ja) | 1998-02-13 | 2002-02-05 | オートイミューン インク | ＣＯＰ−１及びＴｈ−２促進性サイトカインを使用した、多発性硬化症の治療 |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES |
| JP2003521448A (ja) | 1998-07-23 | 2003-07-15 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 合成ペプチドおよび自己免疫疾患治療のための使用方法 |
| ES2408706T3 (es) | 1998-09-25 | 2013-06-21 | Yeda Research And Development Co., Ltd. | Polipéptidos relacionados con el copolímero 1 para su uso como marcadores de pesos moleculares y para uso terapéutico |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2000020010A1 (en) | 1998-10-02 | 2000-04-13 | Yeda Research And Development Co., Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| AU775073C (en) | 1998-11-12 | 2007-05-03 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD |
| US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| US20030104048A1 (en) | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| US6872739B1 (en) | 1999-06-04 | 2005-03-29 | Vereniging Voor Christelijk Wetenshappelikjk Onderwijs | Use of riluzole for the treatment of multiple sclerosis |
| US6531130B1 (en) | 1999-07-06 | 2003-03-11 | The Board Of Trustees Of The Leland Stanford University | Treatment of demyelinating autoimmune disease with ordered peptides |
| HK1054507B (zh) | 2000-01-20 | 2008-10-31 | 耶达研究及发展有限公司 | 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途 |
| MXPA02008023A (es) | 2000-02-18 | 2005-06-30 | Yeda Res & Dev | Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar. |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| CA2411536A1 (en) | 2000-06-05 | 2001-12-13 | V. Wee Yong | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| DE60116467T2 (de) | 2000-06-07 | 2006-11-02 | Yeda Research And Development Co., Ltd. | Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| KR100392501B1 (ko) | 2000-06-28 | 2003-07-22 | 동국제약 주식회사 | 다중 에멀젼법에 의한 서방출성 미립구의 제조방법 |
| US6835711B2 (en) | 2001-06-28 | 2004-12-28 | Yeda Research And Development Co. Ltd. | Use of poly-Glu,Tyr for neuroprotective therapy |
| JP4426286B2 (ja) | 2001-07-10 | 2010-03-03 | テバ ファーマシューティカル インダストリーズ リミティド | ０次、０次−二相性、上昇型又は下降型薬物放出のための薬物送達システム |
| IL161121A0 (en) | 2001-10-03 | 2004-08-31 | Harvard College | Copolymers for suppression of autoimmune diseases, and methods of use |
| EP1434579B1 (en) | 2001-10-09 | 2011-06-08 | Amgen Inc. | Imidazole derivatives as antiinflammatory agents |
| WO2003048207A2 (en) | 2001-11-28 | 2003-06-12 | Immunomedics, Inc. | Anti-dota antibody |
| EP1459065B1 (en) | 2001-12-04 | 2010-07-28 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
| US7351686B2 (en) | 2001-12-06 | 2008-04-01 | Yeda Research And Development Co. Ltd. | Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides |
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| CN1398584A (zh) | 2002-07-15 | 2003-02-26 | 裴福兴 | 一种bFGF－PLGA缓释微球及其制备方法和用途 |
| DE10237146A1 (de) | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
| EP1556053A4 (en) | 2002-10-31 | 2006-04-19 | Amgen Inc | ANTI-INFLAMMATORY AGENTS |
| WO2004043995A2 (en) | 2002-11-13 | 2004-05-27 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
| EP1572271A1 (de) | 2002-11-25 | 2005-09-14 | Tecpharma Licensing AG | Autoinjektor mit rückstellbarer auslösesicherung |
| WO2004060265A2 (en) | 2003-01-07 | 2004-07-22 | Yeda Research And Development Co. Ltd. | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| NZ569331A (en) | 2003-01-21 | 2010-08-27 | Yeda Res & Dev | COP 1 for treatment of inflammatory bowel diseases |
| CA2518079A1 (en) | 2003-03-04 | 2004-10-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| CA2525771A1 (en) | 2003-05-14 | 2004-12-02 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
| US8075919B2 (en) | 2003-07-18 | 2011-12-13 | Baxter International Inc. | Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation |
| US20050142205A1 (en) | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
| US20060276390A1 (en) | 2003-07-31 | 2006-12-07 | Yeda Research And Development Co. Ltd. | Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
| JP2007509981A (ja) | 2003-10-31 | 2007-04-19 | テバ ファーマシューティカル インダストリーズ リミティド | 薬物デリバリー用ナノ粒子 |
| CA2546077C (en) | 2003-11-12 | 2016-07-05 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| KR101242486B1 (ko) | 2004-01-12 | 2013-03-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 장기 전달을 위한 제형 및 그의 이용 방법 |
| RU2006134701A (ru) | 2004-03-01 | 2008-04-10 | Пептиммьюн | Способы и композиции для лечения аутоиммунных заболеваний |
| EP1778286A4 (en) | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| US7576051B2 (en) | 2004-03-11 | 2009-08-18 | Sanyo Chemical Industries, Ltd. | Wound dressing for accelerating epidermal regeneration |
| JP5162236B2 (ja) | 2004-03-25 | 2013-03-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | イミダゾール化合物 |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| US20060194725A1 (en) | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| CA2565819A1 (en) | 2004-05-07 | 2005-12-01 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| SG183012A1 (en) | 2004-06-04 | 2012-08-30 | Genentech Inc | Method for treating multiple sclerosis |
| CA2575604A1 (en) | 2004-07-30 | 2006-02-02 | Oregon Health And Science University | Methods for detecting and treating autoimmune disorders |
| CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| CA2579038A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| DK1799703T3 (da) | 2004-09-09 | 2010-04-19 | Teva Pharma | Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid |
| HRP20160455T1 (hr) | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| DE602005016292D1 (de) | 2004-10-29 | 2009-10-08 | Sandoz Ag | Verfahren zur herstellung von glatiramer |
| CA2587597A1 (en) | 2004-11-19 | 2006-05-26 | Biogen Idec Ma Inc. | Treatment for multiple sclerosis |
| ES2541780T3 (es) | 2004-11-29 | 2015-07-24 | Yeda Research And Development Co., Ltd. | Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1 |
| US20060172942A1 (en) | 2005-02-02 | 2006-08-03 | Teva Pharmaceutical Industries, Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
| AU2006211101A1 (en) | 2005-02-02 | 2006-08-10 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Synthetic peptide copolymers for treatment and prevention of cardiovascular disorders |
| US20080279819A1 (en) | 2005-02-15 | 2008-11-13 | Adamas Pharmaceuticals, Inc. | Combinations Therapy for Treatment of Demyelinating Conditions |
| RS52867B (sr) | 2005-02-17 | 2013-12-31 | Teva Pharmaceutical Industries Ltd. | Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| US20060240463A1 (en) | 2005-04-25 | 2006-10-26 | Rappaport Family Institute For Research In The Medical Sciences | Markers associated with the therapeutic efficacy of glatiramer acetate |
| JP2008545660A (ja) | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
| WO2007021970A2 (en) | 2005-08-15 | 2007-02-22 | Praecis Pharmaceuticals, Inc. | Stable pharmaceutical formulations and methods of use thereof |
| WO2007030573A2 (en) | 2005-09-09 | 2007-03-15 | Yeda Research And Development Co. Ltd. | Polypeptides useful for molecular weight determinations |
| US7517856B2 (en) | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
| US20070161566A1 (en) | 2006-01-11 | 2007-07-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| US8410115B2 (en) | 2006-02-28 | 2013-04-02 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| HUE047230T2 (hu) | 2006-02-28 | 2020-04-28 | Biogen Ma Inc | Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei |
| JP2009530613A (ja) | 2006-03-15 | 2009-08-27 | ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド | 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用 |
| WO2007127977A2 (en) | 2006-04-28 | 2007-11-08 | Momenta Pharmaceuticals, Inc. | Methods of evaluating peptide mixtures |
| WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| JP5412280B2 (ja) | 2006-06-28 | 2014-02-12 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 加齢性黄斑変性症の治療法 |
| CN103316402A (zh) | 2006-06-30 | 2013-09-25 | 艾伯维生物技术有限公司 | 自动注射装置 |
| SI2046817T1 (sl) | 2006-07-05 | 2010-04-30 | Momenta Pharmaceuticals Inc | Izboljšani postopek za pripravo kopolimera-1 |
| MX2009003661A (es) | 2006-10-06 | 2009-04-22 | Baxter Int | Microcapsulas que contienen microparticulas modificadas en la superficie y metodos para formar y utilizar las mismas. |
| RU2009127095A (ru) | 2006-12-15 | 2011-01-20 | Эбботт Лэборетриз (Us) | Новые оксадиазольные соединения |
| WO2008075365A1 (en) | 2006-12-20 | 2008-06-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for treatment of age related degeneration of the retina |
| HUE032251T2 (en) | 2007-02-08 | 2017-09-28 | Biogen Ma Inc | Neuroprotection in demyelinating diseases |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| EP2164498A4 (en) | 2007-06-04 | 2010-09-08 | Univ California | PREGNANCY HORMONE ASSOCIATION FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| CA2693697C (en) | 2007-07-11 | 2017-07-25 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| WO2009040814A1 (en) | 2007-09-24 | 2009-04-02 | Hadasit Medical Research Services & Development Ltd | Use of copolymer 1 for treatment of muscular dystrophy |
| RU2481332C2 (ru) | 2007-09-25 | 2013-05-10 | Эбботт Лэборетриз | Октагидропенталеновые соединения в качестве антагонистов хемокиновых рецепторов |
| US8394763B2 (en) | 2007-09-26 | 2013-03-12 | Oregon Health & Science University | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
| WO2009063459A2 (en) | 2007-11-13 | 2009-05-22 | Yeda Research And Development Co. Ltd | Synthetic peptide copolymers for treatment of neurodevelopmental disorders |
| WO2009070298A1 (en) | 2007-11-28 | 2009-06-04 | Teva Pharmaceutical Industries, Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
| ES2329327B1 (es) | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
| CA2732228A1 (en) | 2008-07-25 | 2010-01-28 | The Johns Hopkins University | Methods and compositions for treating and preventing autoimmune diseases |
| WO2010024908A1 (en) | 2008-08-26 | 2010-03-04 | Fibrogen, Inc. | Methods for treatment of multiple sclerosis |
| CN101827522A (zh) | 2008-09-10 | 2010-09-08 | 阿索尔达治疗股份有限公司 | 持续释放氨基吡啶组合物的使用方法 |
| AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| EP2355660A4 (en) | 2008-10-13 | 2012-05-02 | Biovista Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
| EP2375900B1 (en) | 2008-12-11 | 2016-03-02 | Biovista, Inc. | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles |
| EP2398499B1 (en) | 2009-02-18 | 2017-09-06 | Eyeon Particle Sciences LLC | Bi-functional co-polymer use for ophthalmic and other topical and local applications |
| EP2246048A1 (en) | 2009-04-30 | 2010-11-03 | Santhera Pharmaceuticals (Schweiz) AG | Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis |
| NZ577731A (en) | 2009-06-16 | 2010-08-27 | Innate Therapeutics Ltd | Compositions and methods for treatment of multiple sclerosis |
| PT2275086E (pt) | 2009-07-15 | 2012-05-18 | Teva Pharma | Formulação de volume reduzido de acetato de glatirâmero e métodos de administração |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| AU2013203367C1 (en) | 2009-08-20 | 2018-01-18 | Yeda Research & Development Co., Ltd | Low frequency glatiramer acetate therapy |
| RS55607B1 (sr) | 2009-08-20 | 2017-06-30 | Yeda Research & Development Company Ltd | Niskofrekventna terapija glatiramer acetatom |
| ES2664727T3 (es) | 2009-10-22 | 2018-04-23 | University College Dublin National University Of Ireland, Dublin | Terapia causal de enfermedades o estados asociados con desmielinización del SNC o del SNP |
| US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| WO2011080733A1 (en) | 2010-01-04 | 2011-07-07 | Mapi Pharma Limited | Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof |
| WO2011100636A1 (en) | 2010-02-11 | 2011-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Markers for determination of patient responsiveness |
| DK2533634T3 (en) | 2010-02-12 | 2016-01-25 | Biogen Ma Inc | NEURO PROTECTIVE demyelinating diseases |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| JP2013535474A (ja) | 2010-07-29 | 2013-09-12 | ドクター レディズ ラボラトリーズ リミテッド | グラチラマー酢酸塩の分子量マーカー |
| EP2605797A2 (en) * | 2010-08-20 | 2013-06-26 | Cerulean Pharma Inc. | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
| EA025780B1 (ru) | 2010-10-11 | 2017-01-30 | Тева Фармасьютикал Индастриз Лтд. | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат |
| GB2485169A (en) | 2010-11-03 | 2012-05-09 | Univ Jw Goethe Frankfurt Main | (R)-flurbiprofen for use in the treatment of multiple sclerosis |
| EP2500072A1 (en) | 2011-03-15 | 2012-09-19 | LEK Pharmaceuticals d.d. | A novel process of residual solvent removal |
| CA2832565A1 (en) | 2011-04-08 | 2012-10-11 | Biogen Idec Ma Inc. | Biomarkers predictive of therapeutic responsiveness to ifn.beta. and uses thereof |
| RU2623161C2 (ru) | 2011-04-15 | 2017-06-22 | Компуджен Лтд. | Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака |
| ES2601892T3 (es) | 2011-04-21 | 2017-02-16 | Mapi Pharma Limited | Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes |
| EP3467509B1 (en) | 2011-05-04 | 2025-11-26 | Cellular Technology, Ltd | Cns antigen-specific b cell, t cell and antibody assays and their uses in diagnosis and treatment of multiple sclerosis |
| US20140348861A1 (en) | 2011-05-05 | 2014-11-27 | National Institute Of Immunology | Synthetic peptides and random copolymers for the treatment of autoimmune disorders |
| SI2529757T1 (sl) * | 2011-05-31 | 2014-05-30 | Laboratorios Farmaceuticos Rovi, S.A. | Formulacija paliperidon implantata |
| MX2014004309A (es) | 2011-10-10 | 2015-07-06 | Teva Pharma | Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer. |
| KR20140148411A (ko) | 2012-03-12 | 2014-12-31 | 메디뮨 엘엘씨 | 항-cd19 항체를 이용한 다발성 경화증의 치료 |
| GB201208850D0 (en) | 2012-05-18 | 2012-07-04 | Alphaptose Gmbh | Tri-subsituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis |
| US9132138B2 (en) | 2012-08-27 | 2015-09-15 | Casi Pharmaceuticals, Inc. | Method for the treatment of multiple sclerosis |
| MX2015004436A (es) | 2012-10-09 | 2015-06-24 | Biogen Idec Inc | Tratamientos conjuntos y usos para tratar trastornos desmielinizantes. |
| WO2014058976A2 (en) | 2012-10-10 | 2014-04-17 | Teva Pharmaceutical Industries Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
| JP2016504039A (ja) | 2013-01-04 | 2016-02-12 | テバ ファーマシューティカル インダストリーズ リミティド | グラチラマーアセテート関連医薬品の特性決定 |
| CN105163730B (zh) | 2013-01-08 | 2018-10-30 | 帕萨罗杰卡有限公司 | 用于治疗脱髓鞘疾病的方法和组合物 |
| KR20150119227A (ko) | 2013-02-15 | 2015-10-23 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료 |
| CN105188751A (zh) | 2013-03-12 | 2015-12-23 | 泰华制药工业有限公司 | 利妥昔单抗诱导疗法继而醋酸格拉替雷疗法 |
| US20160040236A1 (en) | 2013-03-15 | 2016-02-11 | Biogen Ma Inc. | Systems and methods for characterization of multiple sclerosis |
| CN103169670B (zh) * | 2013-03-22 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷微球及其制备方法 |
| EP3043819A4 (en) | 2013-09-11 | 2017-04-05 | Compugen Ltd. | Anti-vstm5 antibodies and the use thereof in therapy and diagnosis |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US10493122B2 (en) | 2014-03-17 | 2019-12-03 | Mapi Pharma Ltd. | Sublingual delivery of glatiramer acetate |
| WO2015168000A1 (en) | 2014-04-28 | 2015-11-05 | The Regents Of The University Of California | Estrogen combination for treatment of multiple sclerosis |
| EP3188735A4 (en) | 2014-09-02 | 2018-01-24 | The Regents of the University of California | Estrogen therapy for brain gray matter atrophy and associated disability |
| US10758496B2 (en) | 2014-09-02 | 2020-09-01 | The Regents Of The University Of California | Estrogen receptor ligand treatment for neurodegenerative diseases |
| US20170306402A1 (en) | 2014-09-12 | 2017-10-26 | Biogen Ma Inc. | Systems and methods for characterization of multiple sclerosis |
| WO2016064997A1 (en) | 2014-10-22 | 2016-04-28 | The Regents Of The University Of California | Compositions and methods for treating fatigue and depression |
| WO2016112270A1 (en) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
| US20160213633A1 (en) | 2015-01-28 | 2016-07-28 | Teva Pharmaceutical Industries, Ltd. | Method of inducing anti-glatiramer acetate antibody response |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| WO2016160830A1 (en) | 2015-03-30 | 2016-10-06 | The Regents Of The University Of California | Methods of providing neuroprotective therapy |
| US10406169B2 (en) | 2015-03-30 | 2019-09-10 | The Regents Of The University Of California | Methods of monitoring estriol therapy |
| EP3478300B1 (en) * | 2016-06-30 | 2022-08-24 | Stem Cell Medicine Ltd. | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells |
| WO2018042423A1 (en) * | 2016-08-28 | 2018-03-08 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| IL316573A (en) | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| EP3624815A4 (en) | 2017-05-15 | 2021-01-20 | Stem Cell Medicine Ltd. | TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS |
-
2017
- 2017-08-09 AU AU2017319728A patent/AU2017319728B2/en active Active
- 2017-08-09 BR BR112019003594-0A patent/BR112019003594A2/pt not_active Application Discontinuation
- 2017-08-09 HU HUE17845658A patent/HUE062393T2/hu unknown
- 2017-08-09 ES ES17845658T patent/ES2952044T3/es active Active
- 2017-08-09 CN CN201780068092.9A patent/CN109982712A/zh active Pending
- 2017-08-09 SM SM20250136T patent/SMT202500136T1/it unknown
- 2017-08-09 HR HRP20230738TT patent/HRP20230738T1/hr unknown
- 2017-08-09 PL PL23173177.9T patent/PL4252849T3/pl unknown
- 2017-08-09 LT LTEPPCT/IL2017/050882T patent/LT3506921T/lt unknown
- 2017-08-09 JP JP2019508893A patent/JP7193448B2/ja active Active
- 2017-08-09 ES ES23173177T patent/ES3023741T3/es active Active
- 2017-08-09 WO PCT/IL2017/050882 patent/WO2018042415A1/en not_active Ceased
- 2017-08-09 RS RS20250341A patent/RS66690B1/sr unknown
- 2017-08-09 RS RS20230617A patent/RS64445B1/sr unknown
- 2017-08-09 HR HRP20250396TT patent/HRP20250396T1/hr unknown
- 2017-08-09 HU HUE23173177A patent/HUE071047T2/hu unknown
- 2017-08-09 FI FIEP17845658.8T patent/FI3506921T3/fi active
- 2017-08-09 DK DK17845658.8T patent/DK3506921T3/da active
- 2017-08-09 SM SM20230251T patent/SMT202300251T1/it unknown
- 2017-08-09 US US16/328,582 patent/US12370233B2/en active Active
- 2017-08-09 PT PT178456588T patent/PT3506921T/pt unknown
- 2017-08-09 EP EP23173177.9A patent/EP4252849B1/en active Active
- 2017-08-09 MX MX2019002284A patent/MX2019002284A/es unknown
- 2017-08-09 IL IL301455A patent/IL301455B2/en unknown
- 2017-08-09 SI SI201731391T patent/SI3506921T1/sl unknown
- 2017-08-09 EP EP17845658.8A patent/EP3506921B1/en active Active
- 2017-08-09 CA CA3035147A patent/CA3035147A1/en active Pending
- 2017-08-09 PL PL17845658.8T patent/PL3506921T3/pl unknown
-
2019
- 2019-02-19 IL IL264914A patent/IL264914B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017319728B2 (en) | Depot systems comprising glatiramer acetate | |
| US12343371B2 (en) | Method for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using a sustained release depot formulation comprising glatiramer acetate | |
| US8377885B2 (en) | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof | |
| AU2010337822A1 (en) | Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof | |
| TW201138805A (en) | Composition of organic compounds | |
| USRE50301E1 (en) | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof | |
| HK40005874A (en) | Depot systems comprising glatiramer acetate | |
| HK40010052A (en) | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220516 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240729 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250415 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250806 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250806 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250807 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250813 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250916 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250916 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260629 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260630 |